TrialBlood advances2019

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Farrukh T Awan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.